Compositions and methods for elimination of unwanted cells

Details Compositions and methods for elimination of unwanted cells Compositions and methods for elimination of unwanted cells

2007-10-31

2010-12-07

Chen, Shin-Lin (Department: 1632)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Genetically modified micro-organism, cell, or virus

C435S320100, C435S455000, C536S023720

Reexamination Certificate

active

07846429

ABSTRACT:
Disclosed are compositions comprising a recombinant nucleic acid vector including a nucleotide sequence encoding a syncytium-inducing polypeptide expressible on a eukaryotic cell surface, and a host cell containing the recombinant vector and expressing the syncytium inducing polypeptide on its cell surface, the vectors and resultant host cells expressing the syncytium inducing polypeptide being useful for selective elimination of unwanted cells.

REFERENCES:
patent: 5753499 (1998-05-01), Meruelo et al.
patent: 5843723 (1998-12-01), Dubensky et al.
patent: 5847096 (1998-12-01), Schubert et al.
patent: 5858687 (1999-01-01), Manger et al.
patent: 5869036 (1999-02-01), Belshe et al.
patent: 5882893 (1999-03-01), Goodearl
patent: 6750206 (2004-06-01), Russell et al.
patent: 7317004 (2006-03-01), Russell et al.
patent: 7314868 (2008-01-01), Russell et al.
patent: 0 790 312 (1997-08-01), None
patent: 0 449 116 (1999-08-01), None
patent: 11-506317 (1996-11-01), None
patent: 8-512199 (1996-12-01), None
patent: 10-4979 (1998-01-01), None
patent: WO 94/25600 (1994-11-01), None
patent: WO 96/30030 (1996-03-01), None
patent: WO 97/03357 (1997-01-01), None
GenBank Accession No. D00090 dated Feb. 11, 2000.
GenBank Accession No. D00093 dated Mar. 11, 1998.
GenBank Accession No. D00125 dated Feb. 11, 2000.
GenBank Accession No. D00731 dated May 29, 2002.
GenBank Accession No. D11446 dated Feb. 3, 2007.
GenBank Accession No. J03911 dated Aug. 2, 1993.
GenBank Accession No. L15085 dated Feb. 18, 1997.
GenBank Accession No. M12294 dated May 8, 2002.
GenBank Accession No. M14923 dated May 15, 1995.
GenBank Accession No. M17641 dated Aug. 2, 1993.
GenBank Accession No. M21417 dated Aug. 3, 1993.
GenBank Accession No. M21849 dated Aug. 2, 1993.
GenBank Accession No. M21881 dated Aug. 2, 1993.
GenBank Accession No. M81895 dated Aug. 2, 1993.
GenBank Accession No. M11486 dated Nov. 29, 2000.
GenBank Accession No. S46730 dated May 8, 1993.
GenBank Accession No. U11736 dated Feb. 8, 2001.
GenBank Accession No. U12388 dated Jan. 4, 1995.
GenBank Accession No. U17064 dated May 24, 1995.
GenBank Accession No. U25806 dated Jul. 23, 1996.
GenBank Accession No. U29433 dated Feb. 25, 1997.
GenBank Accession No. U44483 dated Mar. 25, 1999.
GenBank Accession No. X02342 dated Jul. 26, 1995.
GenBank Accession No. X03896 dated Apr. 18, 2005.
GenBank Accession No. X04797 dated Feb. 15, 2002.
GenBank Accession No. X05303 dated Apr. 18, 2005.
GenBank Accession No. X05597 dated Apr. 18, 2005.
GenBank Accession No. X64275 dated Nov. 14, 2006.
GenBank Accession No. X64737 dated Feb. 3, 1994.
GenBank Accession No. Z15044 dated Aug. 1, 1995.
GenBank Accession No. Z24675 dated Apr. 18, 2005.
GenBank Accession No. X02794 dated Apr. 18, 2005.
GenBank Accession No. X91135 dated Nov. 26, 1996.
Andeweg et al., “Both the V2 and V3 Regions of the Human Immunodeficiency Virus Type 1 Surface Glycoprotein Functionally Interact with Other Envelope Regions in Syncytium Formation,”J. Virol., 1993, 67:3232-3239.
Asada, “Treatment of Human Cancer with Mumps Virus,”Cancer, 1974, 34:1907-1928.
ATCC HTB 30, Human Tumor Cell Bank, pp. 222-223 (Need Date).
Ausubel et al. (eds.),Current Protocols in Molecular Biology, 1989, Greene Publishing Associates, Sections 9.10-9.14.
Baghian et al., “Truncation of the Carboxy-Terminal 28 Amino Acids of Glycoprotein B Specified by Herpes Simplex Virus Type 1 Mutant amb1511-7 Causes Extensive Cell Fusion,”J. Virol., 1993, 67:2396-2401.
Berkner et al., “Development of adenovirus vectors for the expression of heterologous genes,”BioTechniques, 1988, 6:616-629.
Briozzo et al., “In Vitro Degradation of Extracellular Matrix with Mr 52,000 Cathepsin D Secreted by Breast Cancer Cells,”Cancer Res., 1988, 48:3688-3692.
Brody et al., “Postassembly Cleavage of a Retroviral Glycoprotein Cytoplasmic Domain Removes a Necessary Incorporation Signal and Activates Fusion Activity,”J. Virol., 1994, 68:4620-4627.
Cai et al., “Role of Glycoprotein B of Herpes Simplex Virus Type 1 in Viral Entry and Cell Fusion,”J. Virol., 1988, 62:2596-2604.
Cathomen et al., “Preferential Initiation at the Second AUG of the Measles Virus F mRNA: A Role for the Long Untranslated Region,”Virology, 1995, 214:628-632.
Ciambrone and McKeown-Longo, “Vitronectin Regulates the Synthesis and Localization of Urokinase-type Plasminogen Activator in HT-1080 Cells,”J. Biol. Chem., 1992, 267:13617-13622.
Cohen et al., “Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease,”J. Endocrinol., 1994, 142:407-415.
Conese and Blasi, “The urokinase/urokinase-receptor system and cancer invasion,”Baillieres Clin. Haematol., 1995, 8:365-389.
Cosset and Russell, “Targeting retrovirus entry,”Gene Therapy, 1996, 3:946-956.
Cosset et al., “High-Titer Packaging Cells Producing Recombinant Retroviruses Resistant to Human Serum,”J. Virol., 1995, 69:7430-7436.
Cosset et al., “Retroviral Retargeting by Envelopes Expressing an N-Terminal Binding Domain,”J. Virol., 1995, 69:6314-6322.
Crystal, “Transfer of Gene to Human Early Lessons and Obstacles to Success,”Science, 1995, 270:404-410.
Danø et al., “Plasminogen Activators, Tissue Degradation, and Cancer,”Adv. Cancer Res., 1985, 44:139-266.
Davis, “The many faces of epidermal growth factor repeats,”The New Biologist, 1990, 2(5):410-419.
Daya et al., “Cholesterol Enhances Mouse Hepatitis Virus-Mediated Cell Fusion,”Virol., 1988, 163:276-283.
Denesvre et al., “TM Domain Swapping of Murine Leukemia Virus and Human T-Cell Leukemia Virus Envelopes Confers Different Infectious Abilities despite Similar Incorporation into Virions,”J. Virol., 1996, 70:4380-4386.
Deonarain, “Ligand-targeted receptor-mediated vector for gene delivery,”Exp. Opin. Ther. Pat., 1998, 8:53-69.
Durrant et al., “Antigenicity of newly established colorectal carcinoma cell lines,”Br. J. Cancer, 1986, 53:37-45.
Duus et al., “Cell Surface Expression and Fusion by the Varicella-Zoster Virus gH:gL Glycoprotein Complex: Analysis by Laser Scanning Confocal Microscopy,”Virology, 1995, 210:429-440.
Dvorak, “Thrombosis and Cancer,”Hum. Pathol., 1987, 18:275-284.
Eck et al., “Gene-Based Therapy,”Goodman&Gildman's The Pharmacological Basis of Therapuetics, 1996, 9th Edition, Chapter 5, pp. 77-101.
Edwards et al., “Human Tumor Procoagulants: Registry of the Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee, International Society on Thrombosis and Haemostasis,”Thromb. Haemost., 1993, 69:205-213.
Forrester et al., “Construction and Properties of a Mutant of Herpes Simplex Virus Type 1 with Glycoprotein H Coding Sequences Deleted,”J. Virol., 1992, 66:341-348.
Gage et al., “Syncytium-Inducing Mutations Localize to Two Discrete Regions within the Cytoplasmic Domain of Herpes Simplex Virus Type 1 Glycoprotein B,”J. Virol., 1993, 67:2191-2201.
Galanis et al., “Use of Viral Fusogenic Membrane Glycoproteins as Novel Therapeutic Transgenes in Gliomas,”Human Gene Therapy, 2001, 12:811-821.
Gething et al., “Studies on the Mechanism of Membrane Fusion: Site-specific Mutagenesis of the Hemagglutinin of Influenza Virus,”J. Cell Biol., 1986, 102:11-23.
Gong et al., “Vaccinia Virus Induces Cell Fusion at Acid pH and This Activity Is Mediated by the N-Terminus of the 14-kDa Virus Envelope Protein,”Virology, 1990, 178:81-91.
Gordon and Cross, “A Factor X-Activating Cysteine Protease from Malignant Tissue,”J. Clin. Invest., 1981, 67:1665-1671.
Heminway et al., “Analysis of Respiratory Syncytial Virus F, G, and SH Proteins in Cell Fusion,”Virology, 1994, 200:801-805.
Hermonat et al., “Use of adeno-associated virus as a mammalian DNA cloning vector:

Affiliated with

Also associated with

Rating

Compositions and methods for elimination of unwanted cells does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions and methods for elimination of unwanted cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for elimination of unwanted cells will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4188555